How to Get Zetia (Ezetimibe) in Nevada

What Ezetimibe Is and Why Nevada Clinicians Prescribe It

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 54% and lowering LDL-C by 15-25% as monotherapy. The IMPROVE-IT trial (N=18,144), published in the New England Journal of Medicine in 2015, remains the definitive outcomes trial: adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint (cardiovascular death, major coronary event, or nonfatal stroke) from 34.7% to 32.7% over a median 6-year follow-up, an absolute risk reduction of 2.0 percentage points (P<0.016) [1]. That modest but statistically significant difference translated to a number needed to treat of approximately 50 over 7 years.

The FDA approved ezetimibe (Zetia) in October 2002 as an adjunct to diet and statin therapy for primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia [2]. The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states that ezetimibe is a "reasonable addition" to maximally tolerated statin therapy when LDL-C remains above goal, particularly in very-high-risk patients [3].

Nevada has one of the fastest-growing populations in the United States, yet many rural counties lack ready access to cardiologists. Telehealth closes that gap for straightforward lipid management, making ezetimibe one of the more commonly initiated cholesterol medications through remote visits.

Generic ezetimibe costs as little as $15-30 for a 30-day supply at major Nevada pharmacy chains, making adherence economics favorable once a prescription is in hand [4].

Who Can Prescribe Zetia in Nevada

Any licensed prescriber with authority to write Schedule N/A Rx-only medications may prescribe ezetimibe in Nevada. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

Nevada granted NPs full practice authority in 2013 under NRS 632.237. NPs in Nevada do not require a physician collaboration agreement, so they can independently manage outpatient lipid therapy including initiating ezetimibe, titrating statins, and ordering follow-up labs [5]. PAs practice under a written supervision agreement with a supervising physician per NRS 630.271, but that agreement does not restrict what medications the PA can prescribe within their scope of practice [6].

Telehealth providers licensed in Nevada or operating under the interstate medical licensure compact may prescribe ezetimibe after conducting a synchronous audio-visual visit that meets the standard of care for a new patient evaluation. Asynchronous ("store-and-forward") prescribing of new medications is generally not considered sufficient for an initial lipid evaluation in Nevada, though established patients may use asynchronous messaging for refills at the prescriber's discretion.

The Nevada State Board of Pharmacy requires that any prescription transmitted electronically to a Nevada pharmacy comply with NRS 639.2328 [7]. Controlled substances have additional requirements, but ezetimibe is not a controlled substance, so standard e-prescribing or written Rx transmission applies.

Telehealth Pathways to a Zetia Prescription in Nevada

Telehealth is a practical first stop for most Nevada patients seeking ezetimibe. Several national platforms hold Nevada medical licenses, and the state's telehealth parity law (SB 420, 2021) requires commercial insurers to reimburse synchronous telehealth visits at the same rate as in-person visits for covered services [8].

A typical telehealth pathway looks like this. The patient books a 20-30 minute video visit focused on cardiovascular risk and lipid goals. The clinician reviews the lipid panel (drawn at a nearby LabCorp, Quest, or hospital outreach lab), calculates 10-year atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations [9], and determines whether ezetimibe is indicated as primary or add-on therapy. If indicated, the prescription is sent electronically to the patient's preferred Nevada pharmacy, often within minutes of the visit ending.

HealthRX clinicians use a three-tier decision framework for ezetimibe initiation in telehealth visits:

Tier 1 (Start same visit): Patient already on maximally tolerated statin, LDL-C above 70 mg/dL in very-high-risk category or above 100 mg/dL in high-risk category, fasting lipid panel drawn within 90 days, no active hepatic disease, no pregnancy.

Tier 2 (Order labs first, follow-up visit): No recent lipid panel, or LDL-C at borderline levels where ASCVD risk calculator input is needed before deciding.

Tier 3 (Refer to cardiology): Suspected familial hypercholesterolemia (LDL-C above 190 mg/dL), statin intolerance requiring full evaluation, or prior PCSK9 inhibitor therapy requiring reassessment.

Most straightforward cases fall into Tier 1 or Tier 2, meaning the vast majority of Nevada telehealth patients can receive a prescription within one to five business days from initial contact.

Labs Required Before Starting Ezetimibe in Nevada

A fasting lipid panel is the minimum pre-prescription laboratory requirement. Patients should fast for 9-12 hours before the draw to ensure an accurate triglyceride value, which affects the Friedewald LDL-C calculation [10].

The core fasting lipid panel includes total cholesterol, LDL-C (calculated or direct), HDL-C, and triglycerides. If triglycerides exceed 400 mg/dL, the Friedewald equation is unreliable and a direct LDL-C measurement or non-HDL-C should be used instead [11].

Liver function tests (AST, ALT) are not required before starting ezetimibe by current ACC/AHA guidelines because ezetimibe has not demonstrated clinically significant hepatotoxicity in trials. The IMPROVE-IT trial reported no excess liver enzyme elevations in the ezetimibe arm compared to placebo [1]. However, many Nevada clinicians obtain a comprehensive metabolic panel at baseline to have a reference value, particularly when combining ezetimibe with a statin.

A thyroid-stimulating hormone (TSH) level is recommended when dyslipidemia is newly diagnosed, as hypothyroidism is a secondary cause of elevated LDL-C that should be treated before or alongside lipid-lowering therapy per AHA/ACC guidance [3].

Patients who have an existing lipid panel dated within the past 6-12 months from a prior provider can typically use that result for a telehealth visit without a repeat draw, saving time and cost.

Nevada has Quest Diagnostics patient service centers in Las Vegas, Henderson, Reno, Sparks, and Carson City, plus LabCorp sites in the same metro areas. Rural residents may use hospital outreach labs or mobile phlebotomy services that ship samples to a central laboratory.

How Nevada Insurance Covers Zetia

Coverage varies substantially by payer type.

Commercial insurance: Most commercial plans in Nevada cover generic ezetimibe on formulary Tier 2 or Tier 3. A 30-day supply commonly carries a $10-45 copay after any deductible. Brand-name Zetia may require a prior authorization or step therapy demonstrating that the generic was tried first, given it is therapeutically equivalent [12].

Medicare Part D: Generic ezetimibe is covered under most Part D formularies in Nevada, typically at Tier 1 or Tier 2. The 2023 Inflation Reduction Act caps out-of-pocket costs for Part D beneficiaries, reducing the financial barrier for long-term users [13].

Nevada Medicaid: As of 2025, Nevada Medicaid does not cover ezetimibe as an adjunct treatment for routine hyperlipidemia. Medicaid enrollees seeking ezetimibe should ask their prescriber about a Medical Exception Request (MER), which requires documentation of medical necessity, a history of statin intolerance, or a specific diagnosis such as homozygous familial hypercholesterolemia. The state Medicaid preferred drug list is maintained by the Nevada Division of Health Care Financing and Policy [14].

Uninsured / cash-pay: Generic ezetimibe 10 mg retails for $10-30 per 30 tablets at Walmart, Costco, and most Nevada grocery chain pharmacies. GoodRx and similar discount programs can reduce the cost to under $15 at many locations. The Merck Patient Assistance Program covers brand Zetia for eligible uninsured patients who meet income criteria [15].

Prior Authorization in Nevada: What Documentation You Need

Prior authorization (PA) for ezetimibe is most commonly triggered for brand-name Zetia, certain Medicare Part D plans, and occasionally for commercial plans using step therapy protocols. Nevada law (SB 378, 2021) requires insurers to make PA decisions within 72 hours for non-urgent requests and 24 hours for urgent requests [16].

A complete PA submission for ezetimibe typically requires: the patient's diagnosis code (E78.00 for pure hypercholesterolemia, E78.5 for hyperlipidemia unspecified), current and historical LDL-C values with dates, documentation of current statin therapy and dose (or explanation of statin intolerance), ASCVD risk score or diagnosis of ASCVD event, and a brief statement of clinical necessity from the prescriber.

If step therapy applies, the plan may require documentation that the patient tried and failed to reach LDL-C goal on a maximally tolerated statin alone before ezetimibe can be approved. "Failed" means LDL-C remains above the risk-stratified target after at least 8 weeks on the statin.

Nevada's step therapy override law (NRS 695C.1755) allows a patient to request an exception to step therapy requirements if the required step-therapy drug is contraindicated, has caused an adverse reaction, or the prescriber documents that the required drug is not clinically appropriate for the patient [17].

The ACC/AHA 2022 guideline states: "For patients with clinical ASCVD in whom LDL-C level remains above 70 mg/dL on maximally tolerated statin therapy, it is reasonable to add ezetimibe to statin therapy." [3] Quoting this guideline language directly in the PA letter often satisfies medical necessity requirements.

Pharmacy Access: Where to Fill a Zetia Prescription in Nevada

Generic ezetimibe is stocked at virtually every retail pharmacy in Nevada. Major chains with Nevada locations include CVS, Walgreens, Walmart Pharmacy, Smith's (Kroger), Raley's, and Costco Pharmacy. All accept e-prescriptions transmitted directly from telehealth platforms.

Mail-order pharmacies accredited by NABP (formerly VIPPS-accredited) can ship to Nevada addresses. A 90-day supply through mail order typically costs less than three separate 30-day fills and reduces the number of pharmacy trips needed [18].

503A compounding pharmacies in Nevada are licensed by the Nevada State Board of Pharmacy and may compound ezetimibe-containing preparations for patients with specific documented medical needs, such as swallowing difficulties requiring a liquid formulation. Compounding under 503A applies to individually prescribed preparations, not bulk supply. Nevada 503A pharmacies must comply with USP <795> standards for non-sterile preparations [19]. Patients should verify that their compounding pharmacy holds an active Nevada 503A registration before placing an order; the Nevada Board of Pharmacy maintains a public licensee lookup at its website.

A 503B outsourcing facility may not ship compounded ezetimibe directly to patients without a valid individual prescription and a qualifying medical need that cannot be met by the commercially available product. The FDA's guidance on 503B facilities clarifies these distinctions [20].

Transferring an Existing Zetia Prescription to Nevada

Patients relocating to Nevada or spending extended time in the state can transfer an existing ezetimibe prescription to a Nevada pharmacy under state and federal rules.

Federal law (21 CFR Part 1306) and Nevada NRS 639.2328 permit transfer of a non-controlled substance prescription between pharmacies once. Chain pharmacies with locations in multiple states (CVS, Walgreens, Walmart) can typically transfer records internally using their shared systems, which does not count against the one-transfer rule [7].

To initiate a transfer, the patient calls or visits the Nevada pharmacy and provides: the name and phone number of the out-of-state pharmacy, the prescription number, and the prescriber's name and contact. The Nevada pharmacist contacts the originating pharmacy directly.

If fewer than 12 months remain on the original prescription (most Rx for chronic medications are written for 1 year with monthly refills), the Nevada pharmacist fills only the remaining authorized refills. Once the transferred prescription is exhausted, a new prescription from a Nevada-licensed prescriber or a telehealth provider licensed in Nevada is required. A brief telehealth visit is often the fastest path to continuity.

What to Expect After Starting Ezetimibe

The LDL-C lowering effect of ezetimibe 10 mg once daily is apparent within 2 weeks of initiation. Most patients reach their new steady-state LDL-C by 4 weeks [21]. A follow-up fasting lipid panel at 4-12 weeks after starting therapy lets the prescriber confirm response and document goal attainment for insurance records.

Ezetimibe is generally well tolerated. The most common adverse effects reported in IMPROVE-IT were diarrhea (4.1% ezetimibe vs. 3.7% placebo) and arthralgia (6.0% vs. 5.7%), rates close enough to placebo to be clinically unremarkable [1]. Muscle symptoms, the dominant concern with statins, are not elevated with ezetimibe monotherapy.

Drug interactions are limited but worth noting. Cyclosporine substantially increases ezetimibe plasma levels; the combination requires dose monitoring. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption and should be taken at least 2 hours after or 4 hours before ezetimibe if co-administered [2].

The 2022 ACC/AHA guideline recommends repeating the lipid panel 4-12 weeks after any statin or non-statin lipid therapy change and every 3-12 months thereafter to assess both adherence and response [3]. Nevada telehealth platforms can order follow-up labs through the same Quest or LabCorp network used at baseline, keeping the entire management cycle remote-friendly.

Patients who do not reach LDL-C goal on combined statin plus ezetimibe therapy may be candidates for PCSK9 inhibitor therapy (evolocumab or alirocumab), both of which are FDA-approved and prescribable by telehealth in Nevada with appropriate documentation [22]. The 2018 ACC/AHA Multi-Society Cholesterol Guideline threshold for adding a PCSK9 inhibitor in very-high-risk patients is an LDL-C at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe [23].